Pages that link to "Q40019405"
Jump to navigation
Jump to search
The following pages link to HCV796: A selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus (Q40019405):
Displaying 50 items.
- Inhibitors of the Hepatitis C Virus Polymerase; Mode of Action and Resistance (Q26783056) (← links)
- Animal models for the study of HCV (Q26797836) (← links)
- MK-7009, a Potent and Selective Inhibitor of Hepatitis C Virus NS3/4A Protease (Q27490545) (← links)
- Discovery of SCH 900188: A Potent Hepatitis C Virus NS5B Polymerase Inhibitor Prodrug As a Development Candidate (Q27684231) (← links)
- Cellular growth kinetics distinguish a cyclophilin inhibitor from an HSP90 inhibitor as a selective inhibitor of hepatitis C virus (Q28480556) (← links)
- Mechanisms of activity and inhibition of the hepatitis C virus RNA-dependent RNA polymerase (Q30318760) (← links)
- Randomized, placebo-controlled, single-ascending-dose study of BMS-791325, a hepatitis C virus (HCV) NS5B polymerase inhibitor, in HCV genotype 1 infection (Q33797808) (← links)
- Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase (Q33798031) (← links)
- Small molecule drug discovery for Dengue and West Nile viruses: applying experience from hepatitis C virus (Q33852451) (← links)
- Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: insights into compound modes of action (Q33878202) (← links)
- Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system (Q34022926) (← links)
- New HCV therapies on the horizon (Q34150558) (← links)
- Human liver transplantation as a model to study hepatitis C virus pathogenesis (Q34197528) (← links)
- Antiviral strategies in hepatitis C virus infection (Q34251454) (← links)
- The hepatitis C virus core protein can modulate RNA-dependent RNA synthesis by the 2a polymerase (Q34518202) (← links)
- Cross-genotypic examination of hepatitis C virus polymerase inhibitors reveals a novel mechanism of action for thumb binders (Q34597666) (← links)
- Experimental models for hepatitis C viral infection (Q34996679) (← links)
- Animal models for studying hepatitis C and alcohol effects on liver (Q35012721) (← links)
- A highly conserved G-rich consensus sequence in hepatitis C virus core gene represents a new anti-hepatitis C target. (Q35981554) (← links)
- Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir (Q36276803) (← links)
- Oxidative Stress Attenuates Lipid Synthesis and Increases Mitochondrial Fatty Acid Oxidation in Hepatoma Cells Infected with Hepatitis C Virus (Q36489340) (← links)
- Dynamics of resistance mutations to NS3 protease inhibitors in a cohort of Brazilian patients chronically infected with hepatitis C virus (genotype 1) treated with pegylated interferon and ribavirin: a prospective longitudinal study (Q36689877) (← links)
- In vitro characterization of GSK2485852, a novel hepatitis C virus polymerase inhibitor (Q37263558) (← links)
- New therapeutic approaches to hepatitis C virus (Q37489533) (← links)
- Non-Nucleoside Inhibitors of Hepatitis C Virus Polymerase: Current Progress and Future Challenges (Q37855859) (← links)
- New hepatitis C therapies in clinical development (Q37911056) (← links)
- HCV animal models: a journey of more than 30 years (Q37945172) (← links)
- Structure-activity relationships in the development of allosteric hepatitis C virus RNA-dependent RNA polymerase inhibitors: ten years of research (Q38034733) (← links)
- New horizons in hepatitis C antiviral therapy with direct-acting antivirals. (Q38087250) (← links)
- Hepatitis C virus infection and related liver disease: the quest for the best animal model (Q38125192) (← links)
- Chimeric rodents with humanized liver: bridging the preclinical/clinical trial gap in ADME/toxicity studies (Q38169790) (← links)
- Mechanistic characterization of GS-9190 (Tegobuvir), a novel nonnucleoside inhibitor of hepatitis C virus NS5B polymerase (Q38283097) (← links)
- Genotypic and phenotypic analyses of hepatitis C virus variants observed in clinical studies of VX-222, a nonnucleoside NS5B polymerase inhibitor (Q38427538) (← links)
- Treatment of HCV in Patients who Failed First-Generation PI Therapy: a Review of Current Literature. (Q38581478) (← links)
- Preclinical Characterization and In Vivo Efficacy of GSK8853, a Small-Molecule Inhibitor of the Hepatitis C Virus NS4B Protein (Q38844822) (← links)
- Protease Inhibitors Block Multiple Functions of the NS3/4A Protease-Helicase during the Hepatitis C Virus Life Cycle (Q38903369) (← links)
- NS5A inhibitors impair NS5A-phosphatidylinositol 4-kinase IIIα complex formation and cause a decrease of phosphatidylinositol 4-phosphate and cholesterol levels in hepatitis C virus-associated membranes (Q38956355) (← links)
- In vitro phenotypic characterization of hepatitis C virus NS3 protease variants observed in clinical studies of telaprevir (Q39084966) (← links)
- Restoration of the activated Rig-I pathway in hepatitis C virus (HCV) replicon cells by HCV protease, polymerase, and NS5A inhibitors in vitro at clinically relevant concentrations (Q39128752) (← links)
- Pyridine Carboxamides: Potent Palm Site Inhibitors of HCV NS5B Polymerase (Q39157657) (← links)
- Biochemical study of the comparative inhibition of hepatitis C virus RNA polymerase by VX-222 and filibuvir (Q39432758) (← links)
- Natural variation in drug susceptibility to HCV polymerase inhibitors in treatment-naïve HCV patient isolates (Q39627463) (← links)
- In vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (letermovir) against herpesviruses and other human pathogenic viruses. (Q40008760) (← links)
- Development of a New Structural Class of Broadly Acting HCV Non-Nucleoside Inhibitors Leading to the Discovery of MK-8876. (Q40109420) (← links)
- An orally available, small-molecule interferon inhibits viral replication (Q41014830) (← links)
- LC-ESI-MS/MS analysis and pharmacokinetics of GP205, an innovative potent macrocyclic inhibitor of hepatitis C virus NS3/4A protease in rats (Q41255502) (← links)
- An open-label randomized controlled study of pegylated interferon/ribavirin combination therapy for chronic hepatitis C with versus without fluvastatin (Q42661947) (← links)
- Combination of fluvastatin with pegylated interferon/ribavirin therapy reduces viral relapse in chronic hepatitis C infected with HCV genotype 1b. (Q42984305) (← links)
- Discovery of novel HCV polymerase inhibitors using pharmacophore-based virtual screening (Q43036416) (← links)
- Impact of calcineurin inhibitors with or without interferon on hepatitis C virus titers in a chimeric mouse model of hepatitis C virus infection (Q43039673) (← links)